Published in J Infect Dis on March 01, 2008
Emergence and pandemic potential of swine-origin H1N1 influenza virus. Nature (2009) 11.34
MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines. Sci Transl Med (2011) 2.75
Applications of nanotechnology for immunology. Nat Rev Immunol (2013) 1.65
Evaluation of two live attenuated cold-adapted H5N1 influenza virus vaccines in healthy adults. Vaccine (2009) 1.51
Inflammasome-independent role of the apoptosis-associated speck-like protein containing CARD (ASC) in the adjuvant effect of MF59. Proc Natl Acad Sci U S A (2011) 1.43
Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza. PLoS One (2010) 1.40
Vaccination against seasonal influenza A/H3N2 virus reduces the induction of heterosubtypic immunity against influenza A/H5N1 virus infection in ferrets. J Virol (2011) 1.38
H5N1 influenza vaccine formulated with AS03 A induces strong cross-reactive and polyfunctional CD4 T-cell responses. J Clin Immunol (2010) 1.36
Effectiveness and cost-effectiveness of expanded antiviral prophylaxis and adjuvanted vaccination strategies for an influenza A (H5N1) pandemic. Ann Intern Med (2009) 1.33
Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults. Vaccine (2010) 1.28
Safety and immunogenicity of an inactivated influenza A/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: results of a phase I-II randomized clinical trial. J Infect Dis (2008) 1.28
Traditional and new influenza vaccines. Clin Microbiol Rev (2013) 1.22
Human monoclonal antibodies to pandemic 1957 H2N2 and pandemic 1968 H3N2 influenza viruses. J Virol (2012) 1.20
Delta inulin polysaccharide adjuvant enhances the ability of split-virion H5N1 vaccine to protect against lethal challenge in ferrets. Vaccine (2011) 1.20
Evaluation of vaccines for H5N1 influenza virus in ferrets reveals the potential for protective single-shot immunization. J Virol (2009) 1.17
Influenza vaccines. Vaccine (2009) 1.17
H5N1 vaccines in humans. Virus Res (2013) 1.16
H5N1 virus-like particle vaccine elicits cross-reactive neutralizing antibodies that preferentially bind to the oligomeric form of influenza virus hemagglutinin in humans. J Virol (2011) 1.14
A primer on strategies for prevention and control of seasonal and pandemic influenza. Am J Public Health (2009) 1.13
Single- and multiple-clade influenza A H5N1 vaccines induce cross protection in ferrets. Vaccine (2009) 1.09
Safety and immunogenicity of inactivated, Vero cell culture-derived whole virus influenza A/H5N1 vaccine given alone or with aluminum hydroxide adjuvant in healthy adults. Vaccine (2009) 1.07
Safety and immunogenicity of a subvirion inactivated influenza A/H5N1 vaccine with or without aluminum hydroxide among healthy elderly adults. Vaccine (2009) 1.07
Immunogenicity and efficacy of flagellin-fused vaccine candidates targeting 2009 pandemic H1N1 influenza in mice. PLoS One (2011) 1.05
A cell-based H7N1 split influenza virion vaccine confers protection in mouse and ferret challenge models. Influenza Other Respir Viruses (2009) 1.01
Different human vaccine adjuvants promote distinct antigen-independent immunological signatures tailored to different pathogens. Sci Rep (2016) 0.99
Evaluations for in vitro correlates of immunogenicity of inactivated influenza a H5, H7 and H9 vaccines in humans. PLoS One (2012) 0.97
A single immunization with CoVaccine HT-adjuvanted H5N1 influenza virus vaccine induces protective cellular and humoral immune responses in ferrets. J Virol (2010) 0.96
Avian influenza pandemic preparedness: developing prepandemic and pandemic vaccines against a moving target. Expert Rev Mol Med (2010) 0.93
Human antibodies that neutralize respiratory droplet transmissible H5N1 influenza viruses. J Clin Invest (2013) 0.92
Pneumonia immunization in older adults: review of vaccine effectiveness and strategies. Clin Interv Aging (2012) 0.90
A single dose of whole inactivated H7N9 influenza vaccine confers protection from severe disease but not infection in ferrets. Vaccine (2014) 0.89
A rapid Flp-In system for expression of secreted H5N1 influenza hemagglutinin vaccine immunogen in mammalian cells. PLoS One (2011) 0.89
Enhanced immunogenicity, mortality protection, and reduced viral brain invasion by alum adjuvant with an H5N1 split-virion vaccine in the ferret. PLoS One (2011) 0.88
Cross-clade protective immunity of H5N1 influenza vaccines in a mouse model. Vaccine (2008) 0.88
Effect of influenza A(H5N1) vaccine prepandemic priming on CD4+ T-cell responses. J Infect Dis (2014) 0.87
Use of a polyanionic carbomer, Carbopol971P, in combination with MF59, improves antibody responses to HIV-1 envelope glycoprotein. Vaccine (2012) 0.86
Pandemic influenza vaccines - the challenges. Viruses (2009) 0.84
Near-infrared laser adjuvant for influenza vaccine. PLoS One (2013) 0.81
A dose-ranging study of MF59(®)-adjuvanted and non-adjuvanted A/H1N1 pandemic influenza vaccine in young to middle-aged and older adult populations to assess safety, immunogenicity, and antibody persistence one year after vaccination. Hum Vaccin Immunother (2014) 0.81
Improving seasonal and pandemic influenza vaccines. Influenza Other Respir Viruses (2008) 0.81
Point-of-Use Mixing of Influenza H5N1 Vaccine and MF59 Adjuvant for Pandemic Vaccination Preparedness: Antibody Responses and Safety. A Phase 1 Clinical Trial. Open Forum Infect Dis (2014) 0.79
The human potential of a recombinant pandemic influenza vaccine produced in tobacco plants. Hum Vaccin Immunother (2012) 0.78
Bench-to-bedside review: vaccine protection strategies during pandemic flu outbreaks. Crit Care (2010) 0.78
Safety and immunogenicity of influenza whole inactivated virus vaccines: A phase I randomized clinical trial. Hum Vaccin Immunother (2015) 0.77
Cell mediated immune responses following revaccination with an influenza A/H5N1 vaccine. Vaccine (2015) 0.77
Long-term immunogenicity of an inactivated split-virion 2009 pandemic influenza A H1N1 virus vaccine with or without aluminum adjuvant in mice. Clin Vaccine Immunol (2015) 0.75
Extrapolating theoretical efficacy of inactivated influenza A/H5N1 virus vaccine from human immunogenicity studies. Vaccine (2016) 0.75
Preclinical evaluation of the safety and pathogenicity of a live attenuated recombinant influenza A/H7N9 seed strain and corresponding MF59-adjuvanted split vaccine. Oncotarget (2016) 0.75
Priming Vaccination With Influenza Virus H5 Hemagglutinin Antigen Significantly Increases the Duration of T cell Responses Induced by a Heterologous H5 Booster Vaccination. J Infect Dis (2016) 0.75
The burden of respiratory syncytial virus infection in young children. N Engl J Med (2009) 8.95
The underrecognized burden of influenza in young children. N Engl J Med (2006) 8.25
Human metapneumovirus and lower respiratory tract disease in otherwise healthy infants and children. N Engl J Med (2004) 7.71
Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med (2007) 6.54
Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults. N Engl J Med (2015) 6.04
Population-based surveillance for hospitalizations associated with respiratory syncytial virus, influenza virus, and parainfluenza viruses among young children. Pediatrics (2004) 5.74
Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet (2007) 5.50
Community-acquired pneumonia requiring hospitalization among U.S. children. N Engl J Med (2015) 4.90
Pediatric hospitalizations associated with 2009 pandemic influenza A (H1N1) in Argentina. N Engl J Med (2009) 4.70
Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis. J Infect Dis (2004) 4.31
Norovirus and medically attended gastroenteritis in U.S. children. N Engl J Med (2013) 4.09
Intracellular warfare between human influenza viruses and human cells: the roles of the viral NS1 protein. Virology (2003) 3.77
Burden of interpandemic influenza in children younger than 5 years: a 25-year prospective study. J Infect Dis (2001) 3.73
Genetic and environmental determinants of human NK cell diversity revealed by mass cytometry. Sci Transl Med (2013) 3.41
Rhinovirus-associated hospitalizations in young children. J Infect Dis (2007) 3.35
Superiority of reverse-transcription polymerase chain reaction to conventional viral culture in the diagnosis of acute respiratory tract infections in children. J Infect Dis (2004) 3.25
Comparison of the influenza virus-specific effector and memory B-cell responses to immunization of children and adults with live attenuated or inactivated influenza virus vaccines. J Virol (2006) 2.97
Influence of prior influenza vaccination on antibody and B-cell responses. PLoS One (2008) 2.83
Lineage structure of the human antibody repertoire in response to influenza vaccination. Sci Transl Med (2013) 2.71
Cellular immune responses in children and adults receiving inactivated or live attenuated influenza vaccines. J Virol (2006) 2.67
Severe pandemic 2009 H1N1 influenza disease due to pathogenic immune complexes. Nat Med (2010) 2.59
A novel group of rhinoviruses is associated with asthma hospitalizations. J Allergy Clin Immunol (2008) 2.53
Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects. Vaccine (2007) 2.51
Determination of the 50% human infectious dose for Norwalk virus. J Infect Dis (2013) 2.50
Density interactions among Streptococcus pneumoniae, Haemophilus influenzae and Staphylococcus aureus in the nasopharynx of young Peruvian children. Pediatr Infect Dis J (2013) 2.47
Accuracy and interpretation of rapid influenza tests in children. Pediatrics (2007) 2.43
Primary vaccine failure after 1 dose of varicella vaccine in healthy children. J Infect Dis (2008) 2.37
Effect of different vaccination schedules on excretion of oral poliovirus vaccine strains. J Infect Dis (2005) 2.33
Genetic measurement of memory B-cell recall using antibody repertoire sequencing. Proc Natl Acad Sci U S A (2013) 2.25
Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus. Sci Transl Med (2010) 2.21
Clinical practice. Pertussis--not just for kids. N Engl J Med (2005) 2.12
Characterization of functional and phenotypic changes in anti-Gag vaccine-induced T cell responses and their role in protection after HIV-1 infection. Proc Natl Acad Sci U S A (2005) 2.10
Influenza burden for children with asthma. Pediatrics (2008) 2.10
Genetic basis for adverse events after smallpox vaccination. J Infect Dis (2008) 2.09
The CPSF30 binding site on the NS1A protein of influenza A virus is a potential antiviral target. J Virol (2006) 2.05
Increasing rates of nasal carriage of methicillin-resistant Staphylococcus aureus in healthy children. Pediatr Infect Dis J (2005) 2.02
The role of human metapneumovirus in upper respiratory tract infections in children: a 20-year experience. J Infect Dis (2005) 2.02
National impact of universal childhood immunization with pneumococcal conjugate vaccine on outpatient medical care visits in the United States. Pediatrics (2006) 2.01
Systems analysis of sex differences reveals an immunosuppressive role for testosterone in the response to influenza vaccination. Proc Natl Acad Sci U S A (2013) 2.00
Guillain-Barré syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine (2010) 1.99
Prevalence of methicillin-resistant Staphylococcus aureus nasal carriage in the community pediatric population. Pediatr Infect Dis J (2002) 1.99
Analysis of reversions in the 5'-untranslated region of attenuated poliovirus after sequential administration of inactivated and oral poliovirus vaccines. J Infect Dis (2006) 1.98
Limited efficacy of inactivated influenza vaccine in elderly individuals is associated with decreased production of vaccine-specific antibodies. J Clin Invest (2011) 1.94
Poor immune responses to a birth dose of diphtheria, tetanus, and acellular pertussis vaccine. J Pediatr (2008) 1.93
Human coronavirus in young children hospitalized for acute respiratory illness and asymptomatic controls. Pediatr Infect Dis J (2012) 1.93
Human rhinovirus species associated with hospitalizations for acute respiratory illness in young US children. J Infect Dis (2011) 1.93
Focal and generalized folliculitis following smallpox vaccination among vaccinia-naive recipients. JAMA (2003) 1.91
Parainfluenza virus infection of young children: estimates of the population-based burden of hospitalization. J Pediatr (2009) 1.90
Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/2004 (H5N1) vaccine after priming with an antigenic variant. J Infect Dis (2008) 1.87
Reduction in high rates of antibiotic-nonsusceptible invasive pneumococcal disease in tennessee after introduction of the pneumococcal conjugate vaccine. Clin Infect Dis (2004) 1.84
Rates of hospitalizations for respiratory syncytial virus, human metapneumovirus, and influenza virus in older adults. J Infect Dis (2012) 1.84
Respiratory syncytial virus-associated hospitalizations among children less than 24 months of age. Pediatrics (2013) 1.83
GeneScan reverse transcription-PCR assay for detection of six common respiratory viruses in young children hospitalized with acute respiratory illness. J Clin Microbiol (2003) 1.83
Establishment of diagnostic cutoff points for levels of serum antibodies to pertussis toxin, filamentous hemagglutinin, and fimbriae in adolescents and adults in the United States. Clin Diagn Lab Immunol (2004) 1.80
Immunogenicity and safety of varying dosages of a monovalent 2009 H1N1 influenza vaccine given with and without AS03 adjuvant system in healthy adults and older persons. J Infect Dis (2012) 1.80
Failure of routine diagnostic methods to detect influenza in hospitalized older adults. Infect Control Hosp Epidemiol (2010) 1.77
Apoptosis and other immune biomarkers predict influenza vaccine responsiveness. Mol Syst Biol (2013) 1.75
Trends in antibiotic prescribing for adults in the United States--1995 to 2002. J Gen Intern Med (2005) 1.75
Live and inactivated influenza vaccines induce similar humoral responses, but only live vaccines induce diverse T-cell responses in young children. J Infect Dis (2011) 1.71
The burden of influenza in young children, 2004-2009. Pediatrics (2013) 1.68
Seasonality of invasive pneumococcal disease: temporal relation to documented influenza and respiratory syncytial viral circulation. Am J Med (2005) 1.68
Clinical and immunologic responses to multiple doses of IMVAMUNE (Modified Vaccinia Ankara) followed by Dryvax challenge. Vaccine (2007) 1.67
Direct and indirect effects of rotavirus vaccination upon childhood hospitalizations in 3 US Counties, 2006-2009. Clin Infect Dis (2011) 1.64
Immune responses and antibody decay after immunization of adolescents and adults with an acellular pertussis vaccine: the APERT Study. J Infect Dis (2004) 1.60
Comparative immunogenicity of trivalent influenza vaccine administered by intradermal or intramuscular route in healthy adults. Vaccine (2007) 1.58
Active, population-based surveillance for severe rotavirus gastroenteritis in children in the United States. Pediatrics (2008) 1.58
Differences in antibiotic prescribing among physicians, residents, and nonphysician clinicians. Am J Med (2005) 1.58
Vaccine effectiveness against laboratory-confirmed influenza in children 6 to 59 months of age during the 2003-2004 and 2004-2005 influenza seasons. Pediatrics (2008) 1.56
T cell-dependent production of IFN-gamma by NK cells in response to influenza A virus. J Clin Invest (2004) 1.56
Effectiveness of seasonal vaccine in preventing confirmed influenza-associated hospitalizations in community dwelling older adults. J Infect Dis (2011) 1.54
Impact of maternal immunization on influenza hospitalizations in infants. Am J Obstet Gynecol (2011) 1.52
Effects of aging, cytomegalovirus infection, and EBV infection on human B cell repertoires. J Immunol (2013) 1.51
Combined tetanus, diphtheria, and 5-component pertussis vaccine for use in adolescents and adults. JAMA (2005) 1.51
A cell-based luminescence assay is effective for high-throughput screening of potential influenza antivirals. Antiviral Res (2006) 1.50
Disparities between black and white children in hospitalizations associated with acute respiratory illness and laboratory-confirmed influenza and respiratory syncytial virus in 3 US counties--2002-2009. Am J Epidemiol (2013) 1.50
Prevalence of pertussis antibodies in maternal delivery, cord, and infant serum. J Infect Dis (2004) 1.48
Safety and immunogenicity of LC16m8, an attenuated smallpox vaccine in vaccinia-naive adults. J Infect Dis (2011) 1.48
A high dosage influenza vaccine induced significantly more neuraminidase antibody than standard vaccine among elderly subjects. Vaccine (2009) 1.44
Qualification of the hemagglutination inhibition assay in support of pandemic influenza vaccine licensure. Clin Vaccine Immunol (2009) 1.44
Kinetics of pertussis immune responses to tetanus-diphtheria-acellular pertussis vaccine in health care personnel: implications for outbreak control. Clin Infect Dis (2009) 1.43
Winter viruses: influenza- and respiratory syncytial virus-related morbidity in chronic lung disease. Arch Intern Med (2002) 1.43
Estimating influenza hospitalizations among children. Emerg Infect Dis (2006) 1.41
Reevaluating antibiotic therapy for urinary tract infections in children. Arch Pediatr Adolesc Med (2005) 1.39
Evaluation of the safety and immunogenicity of a booster (third) dose of inactivated subvirion H5N1 influenza vaccine in humans. J Infect Dis (2008) 1.38
Varicella zoster disease of the central nervous system: epidemiological, clinical, and laboratory features 10 years after the introduction of the varicella vaccine. J Infect Dis (2010) 1.36
Secular variation in United States rotavirus disease rates and serotypes: implications for assessing the rotavirus vaccination program. Pediatr Infect Dis J (2009) 1.36
Evaluation of a single dose of half strength inactivated influenza vaccine in healthy adults. Vaccine (2002) 1.36
Periodic fever, aphthous stomatitis, pharyngitis, and adenitis (PFAPA) is a disorder of innate immunity and Th1 activation responsive to IL-1 blockade. Proc Natl Acad Sci U S A (2011) 1.33
Bedside diagnosis of influenzavirus infections in hospitalized children. Pediatrics (2002) 1.32
Cytokine expression patterns associated with systemic adverse events following smallpox immunization. J Infect Dis (2006) 1.29
Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults. Vaccine (2010) 1.28
Humoral and cellular immune responses in children given annual immunization with trivalent inactivated influenza vaccine. Pediatr Infect Dis J (2007) 1.28
Safety and immunogenicity of an inactivated influenza A/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: results of a phase I-II randomized clinical trial. J Infect Dis (2008) 1.28
Immunogenicity of an inactivated monovalent 2009 H1N1 influenza vaccine in pregnant women. J Infect Dis (2011) 1.28